Newsroom

HSSC Joins the Mid-South Clinical Data Research Network

September 15, 2015

HSSC and the Carolinas Collaborative joined the Mid-South Clinical Data Research Network in 2015, part of a national network for conducting clinical effectiveness research through the Patient Centered Outcomes Research Network (PCORnet). This collaboration will allow Carolina-based researchers to access data and collaborate with colleagues from across the country to improve health in America.

The Mid-South Clinical Data Research Network, established by Vanderbilt University in 2014, has been awarded a three-year, $8.5 million in funding from the Patient Centered Outcomes Research Institute (PCORI) as part the second phase of the development of PCORnet. The PCORI funding award enables the Mid-South Clinical Data Research Network to include member of the Carolinas Collaborative including Health Sciences South Carolina.

HSSC President and CEO Helga Rippen said inclusion of the Carolinas Collaborative in the Mid-South Clinical Data Research Network elevates the research opportunities of HSSC’s supported member organizations and the North Carolina universities while leveraging the Clinical and Translational Science awardees (CTSAs) at Duke, MUSC and UNC.

“Our two states have a wealth of talent already conducting transformative research to improve healthcare systems and patients’ health in the Carolinas’” said Rippen. “As members of the Mid-South Clinical Data Research Network, researchers from all of our member organizations will have access to data from nine million people in the Southeast and 14 million nationally. This will enable us to accelerate our efforts to improve health in North and South Carolina, states that face unacceptably high rates of chronic diseases, as well as improve health on a national level.”

Prior to the new PCORI funding award, the Mid-South Clinical Data Research Network had collaborated on more than 30 different research projects, and is actively involved in the national PCORI-funded trial on aspirin dosing and planned PCORI observational studies on obesity. PCORI phase II research, which will include Clemson, MUSC, and USC, will center on improving treatment and outcomes for a wide range of health conditions, including heart disease, diabetes, cancer, sickle cell anemia, sleep apnea, autism, and arthritis.